Cite
HARVARD Citation
Gettinger, S. et al. (n.d.). 1503TiPCheckMate 592: A phase II exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC. Annals of oncology. p. . [Online].